Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell...

Full description

Bibliographic Details
Main Authors: Christian U. Blank, Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Current Oncology
Subjects:
atezolizumab
bevacizumab
checkpoint inhibition
interferon alfa
renal cell carcinoma
Online Access:https://www.mdpi.com/1718-7729/28/6/455

Internet

https://www.mdpi.com/1718-7729/28/6/455

Similar Items